Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



MannKind Corporation Stock Signs Up Sanofi, Investors Conflicted

After years of discussions, MannKind (NASDAQ: MNKD  ) finally has a partner for its inhaled insulin Afrezza.

And a pretty good one at that.

Source: MannKind

The biotech announced a deal with diabetes expert Sanofi (NYSE: SNY  ) yesterday. There are two ways of looking at the deal:

1. MannKind is giving up a lot
The biotech used to own 100% of the rights to Afrezza. Now it owns just 35%.

That's a big haircut. There's no sugarcoating it, MannKind is giving up a lot of upside.

MannKind probably couldn't market Afrezza effectively on its own, so a partnership or a full sale was always expected. But it would have been nice to have seen MannKind retain closer to 50% ownership.

2. Sanofi is offering a lot ... upfront
MannKind gets $150 million up front. That's certainly bigger than the company could have gotten before the approval and shows Sanofi is confident its 65% ownership can produce $150 million in profits fairly quickly.

Sanofi is so confident in the prospects it's even willing to cover MannKind's portion of the losses from the partnership, up to $175 million. It's not actually free money -- it's a loan -- but if Afrezza is a flop, MannKind doesn't have much to fall back on, and Sanofi may never see the loan repaid, making it another sign of Sanofi's confidence.

The deal calls for up to $775 million in milestone payments "dependent upon specific regulatory and development targets, as well as sales thresholds." Given the vague details, it's hard to know how much of those milestones MannKind might eventually get although the biotech did say the sales milestones start at $250 million in aggregate sales, which seems achievable.

The biotech also disclosed the milestone payments include $30 million for EU approval and $20 million for approval in Japan, which aren't long-shots, but aren't sure things necessarily either.

MannKind's good outweighs the bad


The funny thing about this deal is the more bullish you were on Afrezza, the less you should like the deal. If Afrezza becomes a $1 billion blockbuster within a few years, taking a smaller up-front payment and retaining more of the profits would be a better deal.

As someone who's less bullish on Afrezza's potential -- at least in the short term -- it looks like a good deal to me. MannKind gets some much-needed cash and doesn't have to cover any of the losses during the initial launch. Sanofi's $150 million payment and agreement to cover MannKind's share of the losses is a solid endorsement of Afrezza's potential.

Beyond the numbers, the deal also looks good because of the chosen partner. Sanofi is a global diabetes powerhouse with glucose monitors and five diabetes drugs, so it should have an easier time convincing doctors to prescribe Afrezza than a company with limited diabetes experience.

But the question remains
While I like the deal terms and the partner, it does bring up the question of valuation -- I wonder if MannKind looks a little overvalued at a $3.2 billion market cap, given that it just signed away a lot of potential drug profit.

The big question, though, for investors is just how big of a seller Afrezza will be. We'll see soon enough whether Sanofi can make Afrezza a quick blockbuster, as it plans to launch the drug device in the first quarter of next year.

Leaked: This coming blockbuster could make even MannKind jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (4) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 12, 2014, at 10:14 AM, erich69 wrote:

    A little overvalued? Look at Intercept (ICPT) today - that's overvalued! Currently sporting a $6.5B market cap with no sales, no FDA approval, and even if they get FDA approval, not many patients have non-alcoholic steatohepatitis! Investors are just scared because Pfizer didn't do a good job with Exubera and that's all they can compare it to. Whereas they easily boost other biotechs up by 50% in one day for drugs that treat conditions they have no clue about or how many patients will actually be taking the drug if approved

  • Report this Comment On August 12, 2014, at 12:53 PM, pick1998 wrote:

    Love your story, Brian.

  • Report this Comment On August 12, 2014, at 3:36 PM, Canalkid2 wrote:

    I agree that Sanofi is a great partner,and that the deal is fair given that Sanofi is bringing an established global reputation, expertise, complementary drugs and devices, and a proven insulin sales team to the table. I don't agree with the opinion that the share price is overvalued, and with Sanofi in charge of regulatory approvals abroad, I am certain these will come in Europe and Japan. As hinted during the recent conference call, Mannkind has other developments in play. Moreover, the market has overlooked the potential for the technosphere franchise.

    Value is always in the eyes of the beholder, and in general the market attitude toward Mannkind reflects one that is sheepish and poorly informed. It has been noted that the same market that punishes Mannkind for a great deal has no problem sending some companies with unapproved NDAs to the moon. But, then, of course, Mannkind is paying for mistakes that Pfizer made with Exubera.

    Also, a huge short position needs to be covered, and "games" are played to keep the share price manageable.The shorts have bet against this company from the beginning, but they keep getting shown they are wrong. I am certain that the value will be quite different a year from now, (or perhaps earlier if other announcements are made regarding the Technosphere platform). In any case, this is a stock for long term investors.

  • Report this Comment On August 13, 2014, at 11:05 AM, beeniecopter wrote:

    Get a haircut yourself. And get real.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3066875, ~/Articles/ArticleHandler.aspx, 9/2/2015 9:02:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,058.35 -469.68 0.00%
S&P 500 1,913.85 -58.33 0.00%
NASD 4,636.11 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 3:59 PM
MNKD $3.71 Down -0.08 +0.00%
MannKind Corp CAPS Rating: **
SNY $48.11 Down -0.81 +0.00%
Sanofi (ADR) CAPS Rating: *****